Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Retained Earnings (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Retained Earnings for 16 consecutive years, with -$100.0 million as the latest value for Q1 2026.

  • Quarterly Retained Earnings fell 3.39% to -$100.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$100.0 million through Jan 2026, down 3.39% year-over-year, with the annual reading at -$85.0 million for FY2025, 361300.88% down from the prior year.
  • Retained Earnings for Q1 2026 was -$100.0 million at PharmaCyte Biotech, down from -$24127.0 in the prior quarter.
  • The five-year high for Retained Earnings was -$14453.0 in Q3 2022, with the low at -$119.1 million in Q3 2023.
  • Average Retained Earnings over 5 years is -$48.0 million, with a median of -$24143.0 recorded in 2023.
  • Peak annual rise in Retained Earnings hit 99.98% in 2023, while the deepest fall reached 824241.45% in 2023.
  • Over 5 years, Retained Earnings stood at -$15173.0 in 2022, then crashed by 59.12% to -$24143.0 in 2023, then plummeted by 387893.27% to -$93.7 million in 2024, then soared by 99.97% to -$24127.0 in 2025, then tumbled by 414374.12% to -$100.0 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$100.0 million, -$24127.0, and -$23746.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.